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Alzheimer’s disease (AD) is the most common form of demen-
tia and is exacting a tremendous economic and personal toll on
nations as well as families throughout the world and this toll
will continue to grow over the passing decades. This crisis is
compounded by the lack of effective treatments for this disease
and the widespread failure of a multitude of therapeutic clin-
ical trials targeting many identified disease pathways including
amyloid-beta (Aβ), tau, inflammation, oxidative stress and more
(reviewed in Schneider et al., 2014). Regardless of these failures,
all of these disease pathways are likely key players in disease patho-
genesis and improved therapeutics as well as better clinical study
design may yet prove effective. Because reduced clearance of Aβ
has been clinically linked to AD (Mawuenyega et al., 2010), it
is likely important to disease pathogenesis. This research topic
focuses on aspects of Aβ clearance in AD and its therapeutic
relevance.
The research topic on Aβ clearance in AD in Frontiers in
Aging Neuroscience has produced a highly informative collection
of reviews, mini-reviews, opinions, hypothesis and theory arti-
cles, as well as original research articles that cover key aspects
related to Aβ clearance. These aspects include proteolytic degra-
dation, low-density lipoprotein (LDL) receptor related clearance,
cellular signaling pathways related to clearance, and transport/
phagocytosis.
With regards to proteases, Marr and Hafez produced a mini-
review that provides a concise rationale for the amyloid hypoth-
esis of AD and updates recent finding related to the neprilysin-2
(NEP2) enzyme and its potential role in AD (Marr and Hafez,
2014). The other articles concerning proteases present new angles
of looking at this topic. Malcolm Leissring contributed an opin-
ion specifically on the critical role of clearance of intracellular
Aβ in disease pathogenesis; while Miners et al. gave us a review
focused on a dual role for these enzymes in both Aβ clearance
and cerebral perfusion as well as how these process may interact
(Leissring, 2014; Miners et al., 2014). Nalivaeva et al. produced
a comprehensive review of key Aβ-degrading enzymes focusing
on the epigenetic regulation of their expression. This review also
discusses transthyretin (TTR), an Aβ binding protein involved in
its transport/clearance (Nalivaeva et al., 2014). Related to this,
the original article contributed by Philibert et al. includes the
characterization of TTR binding to Aβ and its ability to prevent
oligomerization. This original article also characterizes the direct
Aβ degrading activity of thimet oligopeptidase (EC 3.4.24.15)
(Philibert et al., 2014).
On the subtopic of LDL receptors, Kanekiyo and Bu provided
a review on the role of LDL receptor-related protein 1 (LRP1) in
Aβ endocytosis and signal transduction in relation to AD patho-
genesis (Kanekiyo and Bu, 2014). Also regarding endocytosis (and
LDL receptors), Zhao et al. contributed an original article on the
effects of aging and apolipoprotein E status on glial uptake of
lentiviral-expressed Aβ, showing that apoE4 results in less effi-
cient microglial clearance of Aβ (Zhao et al., 2014). Following
on the subtopic of glial uptake, Bhattacharjee et al. produced an
opinion focusing on miRNA-34a as a regulator of the phago-
cytosis sensor-receptor, TREM2, and its potential role in AD
(Bhattacharjee et al., 2014). Zolezzi et al. provided a comprehen-
sive review of AD pathogenesis and Aβ regulation focusing on
the PPAR signaling pathway; while Hernandez-Rapp et al. wrote
a mini review on PrPc signaling and its effects on Aβ clearance
(Hernandez-Rapp et al., 2014; Zolezzi et al., 2014).
These articles also discuss the therapeutic implications of their
topics. Related to this, Spencer and Masliah provided a review on
the state of immunotherapy for AD and future perspectives on
this type of Aβ clearance-related therapeutic approach (Spencer
and Masliah, 2014). Finally, Qiu and Zhu produced a hypothe-
sis and theory article on the relevance of amylin to AD therapy
(Qiu and Zhu, 2014). Therefore, this compilation of articles is
highly relevant to the study and development of AD therapies.
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